Shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1-year consensus target price of $19.33 for the company, according to Zacks. Zacks has also assigned Aileron Therapeutics an industry rank of 98 out of 265 based on the ratings given to its competitors.

Separately, Canaccord Genuity reissued a “buy” rating and issued a $19.00 price target on shares of Aileron Therapeutics in a report on Friday, August 11th.

Large investors have recently added to or reduced their stakes in the business. Jennison Associates LLC bought a new position in Aileron Therapeutics during the 2nd quarter worth approximately $2,788,000. Sphera Funds Management LTD. bought a new position in Aileron Therapeutics during the 2nd quarter worth approximately $1,394,000. Goldman Sachs Group Inc. bought a new position in Aileron Therapeutics during the 2nd quarter worth approximately $418,000. Neuberger Berman Group LLC bought a new position in Aileron Therapeutics during the 2nd quarter worth approximately $279,000. Finally, Nexthera Capital LP bought a new position in Aileron Therapeutics during the 2nd quarter worth approximately $1,272,000. 7.64% of the stock is currently owned by institutional investors.

Aileron Therapeutics (ALRN) opened at $10.80 on Tuesday. Aileron Therapeutics has a 1-year low of $9.58 and a 1-year high of $15.48.

TRADEMARK VIOLATION WARNING: “Zacks: Aileron Therapeutics, Inc. (ALRN) Receives Average Rating of “Strong Buy” from Analysts” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/05/zacks-aileron-therapeutics-inc-alrn-receives-average-rating-of-strong-buy-from-analysts.html.

About Aileron Therapeutics

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.